Impact of trans-stent gradient on outcome after PCI: results from a HAWKEYE substudy.
Angiography-based fractional flow reserve
Outcome
Percutaneous coronary intervention
Trans-stent gradient
Vessel-oriented composite endpoint
Journal
The international journal of cardiovascular imaging
ISSN: 1875-8312
Titre abrégé: Int J Cardiovasc Imaging
Pays: United States
ID NLM: 100969716
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
30
03
2022
accepted:
04
08
2022
entrez:
29
11
2022
pubmed:
30
11
2022
medline:
2
12
2022
Statut:
ppublish
Résumé
To test whether quantitative flow ratio (QFR)-based trans-stent gradient (TSG) is associated with adverse clinical events at follow-up. A post-hoc analysis of the multi-center HAWKEYE study was performed. Vessels post-PCI were divided into four groups (G) as follows: G1: QFR ≥ 0.90 TSG = 0 (n = 412, 54.8%); G2: QFR ≥ 0.90, TSG > 0 (n = 216, 28.7%); G3: QFR < 0.90, TSG = 0 (n = 37, 4.9%); G4: QFR < 0.90, TSG > 0 (n = 86, 11.4%). Cox proportional hazards regression model was used to analyze the effect of baseline and prognostic variables. The final reduced model was obtained by backward stepwise variable selection. Receiver operating characteristic (ROC) was plotted and area under the curve (AUC) was calculated and reported. Overall, 449 (59.8%) vessels had a TSG = 0 whereas (40.2%) had TSG > 0. Ten (2.2%) vessel-oriented composite endpoint (VOCE) occurred in vessels with TSG = 0, compared with 43 (14%) in vessels with TSG > 0 (p < 0.01). ROC analysis showed an AUC of 0.74 (95% CI: 0.67 to 0.80; p < 0.001). TSG > 0 was an independent predictor of the VOCE (HR 2.95 [95% CI 1.77-4.91]). The combination of higher TSG and lower final QFR (G4) showed the worst long-term outcome while low TSG and high QFR showed the best outcome (G1) while either high TSG or low QFR (G2, G3) showed intermediate and comparable outcomes. Higher trans-stent gradient was an independent predictor of adverse events and identified a subgroup of patients at higher risk for poor outcomes even when vessel QFR was optimal (> 0.90).
Identifiants
pubmed: 36445673
doi: 10.1007/s10554-022-02708-7
pii: 10.1007/s10554-022-02708-7
pmc: PMC9708807
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2819-2827Informations de copyright
© 2022. The Author(s).
Références
Circ Cardiovasc Interv. 2018 Feb;11(2):e006023
pubmed: 29449325
J Am Coll Cardiol. 2004 Jun 2;43(11):1959-63
pubmed: 15172398
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Lancet. 2018 Oct 6;392(10154):1235-1245
pubmed: 30253879
JACC Cardiovasc Interv. 2016 Oct 10;9(19):2024-2035
pubmed: 27712739
Eur Heart J. 2020 Nov 7;41(42):4103-4110
pubmed: 31891653
J Am Heart Assoc. 2020 Feb 4;9(3):e015073
pubmed: 32013707
Eur Heart J. 2019 Aug 1;40(29):2455-2462
pubmed: 30608528
JACC Cardiovasc Interv. 2019 Oct 28;12(20):2079-2088
pubmed: 31563688
Cardiovasc Drugs Ther. 2022 Aug;36(4):645-653
pubmed: 33830399
Catheter Cardiovasc Interv. 2020 Apr 1;95(5):E123-E129
pubmed: 31169345
Circulation. 2019 Jan 29;139(5):694-706
pubmed: 30689413
Circ Cardiovasc Interv. 2019 Feb;12(2):e007030
pubmed: 30732469
Lancet. 2021 Dec 11;398(10317):2149-2159
pubmed: 34742368
Circulation. 2015 Sep 15;132(11):1020-9
pubmed: 26162917
JACC Cardiovasc Imaging. 2015 Nov;8(11):1297-305
pubmed: 26563859
J Am Coll Cardiol. 2021 Mar 9;77(9):1165-1178
pubmed: 33663733
Circ Cardiovasc Interv. 2019 May;12(5):e007428
pubmed: 31018666
J Am Coll Cardiol. 2005 Apr 5;45(7):995-8
pubmed: 15808753
Am Heart J. 2017 Feb;184:10-16
pubmed: 27892882
Catheter Cardiovasc Interv. 2019 Mar 1;93(4):E225-E234
pubmed: 30702187
Lancet. 2016 Jan 23;387(10016):357-366
pubmed: 26520230
JAMA Cardiol. 2019 Apr 1;4(4):370-374
pubmed: 30840026
J Am Heart Assoc. 2018 Jul 6;7(14):
pubmed: 29980523
JACC Cardiovasc Interv. 2018 Oct 22;11(20):2099-2109
pubmed: 30336814
Future Cardiol. 2021 Nov;17(8):1435-1452
pubmed: 33739146
Circ Cardiovasc Interv. 2017 Aug;10(8):
pubmed: 28790165
JACC Cardiovasc Interv. 2021 Feb 8;14(3):237-246
pubmed: 33541534